Kimball Electronics Inc Stock Price, News & Analysis

Kimball Electronics (Nasdaq: KE) has published its 2024 Guiding Principles Report, showcasing the company's sustainability initiatives and ESG progress.

The report, titled 'Strategically Focused', demonstrates Kimball Electronics' commitment to addressing key environmental, social, and governance priorities while ensuring sustainable business growth. The document highlights the company's targeted approach to creating meaningful impact in areas that matter most for both environmental stewardship and stakeholder value.

Kimball Electronics (KE) reported Q2 fiscal 2025 results with net sales of $357.4 million and operating income of $8.2 million (2.3% of net sales). The company generated $29.5 million in operating cash flow, marking the fourth consecutive quarter of positive cash flow. Notable improvements include a $29 million reduction in inventory from Q1 and a $41 million decrease in borrowings.

The company experienced declining customer demand across all segments: Automotive sales decreased 4% to $192.8 million, Medical sales fell 22% to $84.0 million, and Industrial sales dropped 20% to $80.6 million. In response, KE has revised its fiscal year 2025 guidance downward, now projecting net sales between $1.40-$1.44 billion and adjusted operating income of 3.4-3.6% of net sales.

Kimball Electronics (Nasdaq: KE) has announced it will release its second quarter fiscal year 2025 financial results on Tuesday, February 4, 2025, after market close. The company will hold a conference call and live webcast to discuss the results on Wednesday, February 5, 2025, at 10:00 a.m. Eastern Time.

Investors can access the conference call via telephone at 877-407-8293 or +1 201-689-8349. A live webcast will be available at investors.kimballelectronics.com, where a replay will also be archived for those unable to attend the live event.

Kimball Electronics (Nasdaq: KE) has achieved the Highest Overall Customer Ratings in all seven categories of CIRCUITS ASSEMBLY'S 2024 Service Excellence Awards. The categories include Dependability/Timely Delivery, Manufacturing Quality, Responsiveness, Technology, Value for the Price, Flexibility, and Overall Satisfaction.

The awards, presented at the SMTA International Conference, are based solely on direct customer input for Electronics Manufacturing Services (EMS) providers with annual sales over $500 million. This marks a significant achievement for Kimball Electronics, which has participated in the awards program for eleven consecutive years, consistently winning multiple categories. The company previously won awards in all seven categories in 2022, four categories in 2023, and now all seven categories again in 2024.

Kimball Electronics (KE) reported Q1 fiscal 2025 results with net sales of $374.3 million, down 15% year-over-year. Operating income was $9.1 million (2.4% of net sales), with adjusted operating income at 3.4%. The company generated $45.5 million in operating cash flow and reduced borrowings to a 2-year low. As part of strategic restructuring, KE completed the divestiture of its Automation, Test, and Measurement business and announced the closure of its Tampa, FL facility. The company confirmed its FY2025 guidance, projecting net sales of $1.44-1.54 billion and adjusted operating income of 4.0-4.5% of net sales.

Kimball Electronics, Inc. (Nasdaq: KE) has announced the date for reporting its first quarter fiscal year 2025 financial results. The company will release the results on Monday, November 4, 2024, after the market closes. Following this, Kimball Electronics will host a conference call and live webcast to review the results on Tuesday, November 5, 2024, at 10:00 a.m. Eastern Time.

Investors and interested parties can access the conference call by dialing 877-407-8293 (domestic) or +1 201-689-8349 (international). A live webcast of the call will be available at investors.kimballelectronics.com. For those unable to participate in the live event, a replay of the webcast will be archived on the same website.

Kimball Electronics announced its Annual Meeting of Share Owners scheduled for Friday, November 15, 2024, at 10:00 a.m. (EST). The in-person event will take place at the company's corporate office in Jasper, Indiana. The meeting will focus on voting results for formal business and proxy proposals.

Share Owners of record as of September 9, 2024, can vote electronically, online, by mail, or by phone before the meeting. The company will file its proxy statement on Thursday, September 26, 2024, providing details on voting procedures for shareholders.

Kimball Electronics (Nasdaq: KE) has announced its participation in the 2024 Annual Gateway Conference in San Francisco on September 4-5. Jana Croom, the company's CFO, is set to present on September 5 at 9:00 a.m. PT. The presentation will be webcast live and archived on the company's investor relations website.

Investors can access the webcast through the Events & Presentations tab in the Investor Relations section at investors.kimballelectronics.com. In addition to the presentation, Kimball Electronics executives will be available for one-on-one meetings throughout the conference. Interested parties can request an invitation or schedule a meeting by emailing conference@gateway-grp.com.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of Michele Holcomb, PhD, to its board of directors as an independent non-executive director, effective September 23, 2024. Dr. Holcomb brings over 30 years of experience in global healthcare, having held notable positions at Cardinal Health, Teva Pharmaceuticals, and McKinsey & Company. Her expertise in leading transformational growth initiatives and driving organizational progress is expected to complement PureTech's board leadership as the company enters its next phase of growth.

Dr. Holcomb will join the Audit Committee, while Dr. Raju Kucherlapati, Chair of the PureTech Board, will step down from this committee. The appointment is seen as strategic for PureTech's focus on innovating and progressing major advances for patients, leveraging Dr. Holcomb's broad biopharma experience to deliver on the company's commitment to developing innovative medicines and building shareholder value.